Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Christian U BlankMinke W LucasRichard A ScolyerBart A van de WielAlexander M MenziesMarta Lopez-YurdaLotte L HoeijmakersRobyn P M SawJudith M LijnsveltNigel G MaherSaskia M PullemanMaria GonzalezAlejandro Torres AcostaWinan J van HoudtSerigne N LoAnke M J KuijpersAndrew SpillaneW Martin C KlopThomas E PenningtonCharlotte L ZuurKerwin F ShannonBeatrijs A SeinstraRobert V RawsonJohn B A G HaanenSydney Ch'ngKishan A T NaipalJonathan StretchJohannes V van ThienenMichael A RtshiladzeSofie WilgenhofRony KapoorAafke Meerveld-EgginkLindsay G Grijpink-OngeringAlexander C J van AkkooiIrene L M ReijersDavid E GyorkiDirk J GrünhagenFrank M SpeetjensSonja B VliekJoanna PlaczkeLavinia SpainRobert C StassenMona Amini-AdleCéleste LebbéMark B FariesCaroline RobertPaolo Antonio AsciertoRozemarijn van RijnFranchette W P J van den BerkmortelDjura PiersmaAndre van der WesthuizenGerard VreugdenhilMaureen J B AartsMarion A M Stevense-den BoerVictoria AtkinsonMuhammad KhattakMiles C AndrewsAlfons J M van den EertweghMarye J Boers-SonderenGeke A P HospersMatteo S CarlinoJan-Willem B de GrootEllen KapiteijnKarijn P M SuijkerbuijkPiotr RutkowskiShahneen SandhuAstrid A M van der VeldtGeorgina V LongPublished in: The New England journal of medicine (2024)
Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.).